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SUMMARY 
 
The ErbB2 receptor is a proto-oncogene associated with a poor 
prognosis in breast cancer. Herceptin, the only humanized anti-ErbB2 
antibody currently in clinical use, has proved to be an essential tool in 
the immunotherapy of breast carcinoma, but induces cardiotoxicity. 
ErbB2 is involved in the growth and survival pathway of adult 
cardiomyocytes; however its levels in the adult heart are much lower 
than those found in breast cancer cells, the intended targets of anti-
ErbB2 antibodies. Furthermore, Lapatinib, a dual kinase inhibitor of 
EGFR and ErbB2, and Pertuzumab, a new anti-ErbB2 monoclonal 
antibody currently in clinical trials, which recognizes an epitope distant 
from that of Herceptin, have shown relatively low cardiotoxicity in 
clinical trials. 
Two novel human antitumor immunoconjugates, made up of a 
human anti-ErbB2 scFv, Erbicin, fused with either a human RNase or 
the Fc region of a human IgG1, are selectively cytotoxic for ErbB2-
positive cancer cells in vitro and vivo, and target an epitope of ErbB2 
different from that of Herceptin.  
As Herceptin has shown cardiotoxic effects, we evaluated if any 
side effects were exerted also by Erbicin-derived immunoagents (EDIA), 
used as single agents or in combination with anthracyclines. 
Furthermore, we compared the in vitro and in vivo cardiotoxic effects of 
EDIA with those of the other available anti-ErbB2 drugs: Herceptin, 2C4 
(Pertuzumab) and Lapatinib. 
Here we show that EDIA, in contrast with Herceptin, 2C4 and 
Lapatinib, have no toxic effects on human fetal cardiomyocytes in vitro, 
and do not induce additive toxicity when combined with doxorubicin. 
Moreover, EDIA do not impair cardiac function in vivo in mice, 
as evaluated by Color Doppler echocardiography, whereas Herceptin 
significantly reduces radial strain at day 2 and fractional shortening at 
day 7 of treatment in a fashion similar to doxorubicin.  Also 2C4 and 
Lapatinib significantly reduce radial strain after only two days of 
treatment, even though they showed cardiotoxic effects less pronounced 
than those of Herceptin. 
We investigated also the molecular basis of the different 
cardiotoxic effects among the ErbB2 inhibitors by testing their effects on 
the formation of the Neuregulin 1β (HRG)/ErbB2/ErbB4 complex and 
on the activation of its downstream signaling. We report herein that Erb-
hcAb at difference with Herceptin, 2C4 (Pertuzumab) and Lapatinib, 
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does not affect the ErbB2-ErbB4 signaling pathway activated by HRG in 
cardiac cells. 
These findings may have important implications for the 
mechanism and treatment of anti-ErbB2-induced cardiotoxicity, and 
suggest that EDIA could fulfil the therapeutic need of patients ineligible 
to Herceptin treatment due to cardiac dysfunction. Furthermore, these 
results strongly indicate that radial strain could become a reliable marker 
to detect early cardiac dysfunction. 
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RIASSUNTO 
 
Il recettore transmembrana tirosina–chinasico (RTK) ErbB2 è 
iper-espresso su diversi tipi di carcinomi, in particolare in quello 
mammario. 
Attualmente l’unico anticorpo monoclonale umanizzato 
impiegato nella terapia del carcinoma mammario è Herceptin. 
Nonostante la sua efficacia, l’impiego di Herceptin presenta alcuni 
svantaggi, quali l’insorgenza di un fenomeno di resistenza nelle pazienti 
trattate per lungo tempo con il farmaco, e l’induzione di effetti 
cardiotossici, che aumentano in modo considerevole quando Herceptin è 
somministrato in combinazione con le antracicline. 
Allo scopo di ottenere anticorpi più efficienti e privi di tali effetti 
collaterali, nel nostro laboratorio sono stati ingegnerizzati due nuovi 
immunoagenti. A partire dalla fusione di un frammento anticorpale 
umano specifico per ErbB2, chiamato Erbicin, o con una RNasi umana o 
con la regione cristallizzabile di una IgG umana sono stati ottenuti 
rispettivamente Erb-hRNasi ed Erb-hcAb, un anticorpo umano compatto 
così chiamato per le sue ridotte dimensioni (100 KDa) rispetto a quelle 
delle IgG naturali (155 KDa). Entrambi gli immunoagenti derivati da 
Erbicin (EDIA, Erbicin derived immunoagents) legano selettivamente ed 
inibiscono la crescita di cellule ErbB2-positive, sia in vitro che in vivo. 
Risultati recenti hanno inoltre dimostrato che gli EDIA riconoscono un 
epitopo di ErbB2 diverso da quello di Herceptin e che non presentano 
effetti tossici su cellule cardiache di ratto in vitro, nè su modelli animali 
di topo in vivo. Nell’ambito di tale progetto, la mia attività di ricerca ha 
avuto lo scopo di completare la valutazione della cardiotossicità di Erb-
hcAb su cardiomiociti umani, in  assenza o in presenza di antracicline e 
di comprendere quali fossero le basi molecolari della differente 
cardiotossicità tra Erb-hcAb, Herceptin e altri inibitori di recettori 
tirosina chinasici, come Lapatinib o 2C4 (Pertuzumab), l’altro anticorpo 
anti-ErbB2, attualmente in fase di sperimentazione clinica. 
I risultati ottenuti hanno dimostrato che gli EDIA, 
differentemente da Herceptin, 2C4 e Lapatinib, non mostrano effetti 
tossici in vitro su cardiomiociti fetali umani quando utilizzati in 
monoterapia, e non potenziano gli effetti tossici della doxorubicina 
quando impiegati in combinazione con l’antraciclina. Inoltre i due EDIA 
non alterano la funzionalità cardiaca in vivo in modelli sperimentali di 
topo, come dimostrato da studi di ecocardiografia Color doppler con 
analisi speckle tracking. Al contrario, il trattamento con Herceptin 
riduceva in modo significativo lo strain radiale dopo 2 giorni e la 
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frazione di accorciamento del ventricolo sinistro dopo 7 giorni. Anche 
2C4 e Lapatinib riducevano lo strain radiale dopo soli due giorni dal 
trattamento, anche se  era stato precedentemente riportato che i loro 
effetti cardiotossici sono meno pronunciati rispetto a quelli di Herceptin. 
Tali risultati sono stati interpretati alla luce dei diversi 
meccanismi molecolari dei diversi inibitori, chiariti nel corso della mia 
attività sperimentale. Erb-hcAb, a differenza di Herceptin, 2C4 e 
Lapatinib non interferisce con il pathway di sopravvivenza cellulare 
promosso dall’eterodimerizzazione di ErbB2 con ErbB4 in presenza del 
ligando Neuregulina 1β.  
Questi risultati potrebbero avere importanti implicazioni per la 
comprensione del meccanismo e del trattamento della cardiotossicità 
indotta da inibitori di ErbB2, ed indicano un possibile impiego dello 
strain radiale come marcatore per l’identificazione precoce di disfunzioni 
cardiache. Alla luce di questi risultati gli EDIA potrebbero essere 
utilizzati a scopo terapeutico in pazienti che non possono essere trattate 
con Herceptin a causa delle complicanze cardiache. 
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1. INTRODUCTION 
 
Immunotherapy is a precious strategy to overcome the limits of the 
conventional anti-cancer treatments. Indeed, targeting cancer cells via 
antibodies specific for tumor associated surface proteins could fulfil the lack 
of selectivity of radiotherapy and chemotherapy, and is a new interesting 
biomedical approach as it combines the rational drug design with the progress 
in understanding cancer biology. 
ErbB2 (Figure 1) is an attractive target for immunotherapy, as it is a 
transmembrane tyrosine kinase receptor highly expressed on many breast, 
ovary, lung and other carcinoma cells [1-5], whereas in normal tissues it is 
expressed at low levels only in certain epithelial cell types [6]. Overexpression 
of this receptor is associated with progression of malignancy of breast cancer, 
and is a sign of a poor prognosis [7]. Herceptin, the only anti-ErbB2 humanized 
monoclonal antibody approved by FDA for the therapy of mammary 
carcinoma, has proved to be effective in the immunotherapy of breast 
carcinoma [8]. However, large-scale clinical studies with Herceptin, have 
shown that up to 7 % or 28 % of patients suffer from cardiac dysfunction when 
Herceptin is used either in monotherapy, or in combination with anthracyclines, 
respectively [9-11]. 
The mechanism of cardiotoxicity induced by Herceptin has not been yet 
elucidated but it has been supposed to be associated with inhibition of ErbB2 
signaling, as the receptor is thought to participate in an important pathway for 
growth, repair, and survival of adult cardiomyocytes [12-14]. However, ErbB2 
levels in the adult heart are low when compared with the levels found in ErbB2-
overexpressing breast cancer cells, the intended targets of a therapy based on 
anti-ErbB2 antibodies. Furthermore, Lapatinib, a dual kinase inhibitor of the 
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Epidermal Growth Factor Receptor (EGFR/ErbB1) and ErbB2, and 
Pertuzumab, a new anti-ErbB2 monoclonal antibody at present tested in clinical 
trials which recognizes an epitope distant from that of Herceptin, have shown 
relatively low cardiotoxicity [15-17]. If inhibition of ErbB2 was responsible for 
cardiomyocyte dysfunction, then cardiotoxicity would have been expected also 
with the quinazoline  compound and all the other anti-ErbB2 antibodies. Thus, 
Herceptin-associated cardiotoxicity must be explained by some alternative 
mechanisms [18]. The hypothesis has been made that Herceptin cardiotoxicity 
is related to the inhibition of the neuregulin 1-activated pathway which directly 
promotes cardiac myocyte survival via ErbB2/ErbB4 heterodimerization [12]. 
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Figure 1. Schematic representation of ErbB2 receptor 
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ErbB2 and ErbB4 receptors are expressed in differentiated 
cardiomyocytes [19]. Binding of Neuregulin-1β (HRG) to ErbB4 increases its 
kinase activity and leads to heterodimerization with ErbB2 or 
homodimerization with ErbB4, though heterodimer with ErbB2 appears to be a 
more potent signalling complex than homodimer [20], stimulating stronger and 
prolonged intracellular signal transduction [21].  
In vitro studies have suggested that the HRG/ErbB2/ErbB4 complex 
controls cardiomyocytes survival and myofibril disarray [22, 23]. It has also 
been shown that neuregulin1/ErbB4 signaling induces cardiomyocyte 
proliferation thus promoting myocardial regeneration following myocardial 
injury [24]. Despite these findings, the basis of cardiac dysfunction after 
inhibition of this system by Herceptin has remained unclear. 
Two novel human antitumor immunoconjugates were engineered in our 
laboratory by fusion of a human anti-ErbB2 single chain variable antibody 
fragment (scFv) [25], termed Erbicin, with either a human RNase [26], 
denominated Erb-hRNase (Erbicin-human-RNase) (Figure 2), or the Fc region 
of a human IgG1 [27]. The latter has been called Erb-hcAb (Erbicin-human-
compact Antibody) (figure 3) for its “compact” reduced size (100 kDa), 
compared with the full size (155 kDa) of a natural IgG, which should promote 
an increased extravascular diffusion and tumor penetration. Both these Erbicin-
Derived Immunoagents (EDIA) are selectively cytotoxic for ErbB2-positive 
cancer cells in vitro and vivo [26-28]. The antitumor action of Erb-hRNase is 
dependent on the ability of this molecule to be internalized by receptor 
mediated endocytosis and to reach the cytosol where the non toxic and non 
immunogenic human RNase can degrade RNA and exert a selective cytotoxic 
action [29]. Erb-hcAb is also capable of selective binding to malignant ErbB2-
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positive cells and of inhibiting the receptor signaling thus inducing cell cycle 
arrest and apoptosis. Finally, due to the presence of Fc region Erb-hcAb is 
endowed with both ADCC and CDC cytotoxic effects [27].  
More interestingly, EDIA are also active on some Herceptin-resistant 
breast cancer cells both in vitro and in vivo [30]. The sensitivity of these cells to 
treatment with EDIA is likely due to their different epitope [31, 32], since 
EDIA, differently from Herceptin, are capable of inhibiting the signaling 
pathway downstream ErbB2 [30] also in these cells.  
The findings that EDIA recognize an epitope different from that of 
Herceptin [31, 32] led us to ascertain whether they might not present the most 
negative property of Herceptin: cardiotoxicity. 
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Figure 2 Schematic representation of the human immunoRNase 
Erb-hRNase (Erbicin-human-RNase). 
ERBICIN scFv
Fc (IgG1)
ERBICIN
CH3
CH2
CH1
CL
VL
VH
IgG1
M.W.= 155 kDa
M.W.= 100 kDa
M.W.= 27 kDa
 
Figure. 3-The construction of Erb-hcAb, a human compact anti-ErbB2 
antibody. Left: Erbicin, the parental  anti-ErbB2 scFv. Right: Erb-hcAb. 
VH and VL are the heavy and light chain variable domains, respectively, 
as derived from Erbicin. H, the hinge region with disulfide bridges. CH2 
and CH3 are the heavy chain constant domains of a human IgG1. Bottom: 
a full size IgG1 
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EDIA did not show in vitro adverse effects on rat cardiomyocytes and 
cardiomyoblasts for which Herceptin is severely toxic [33]. These differences 
have been found to be due to their different mechanism of action: in fact 
Herceptin, differently from Erb-hcAb, induces apoptosis in cardiac cells. In 
vivo studies on a mouse model have shown that EDIA do not alter the cardiac 
function, whereas Herceptin significantly reduces fractional shortening (FS) in 
a fashion similar to that of doxorubicin [33].  
Furthermore, we demonstrated that the treatment with either Erb-hcAb 
or Erb-hRNase induced in treated mice cardiac fibrosis and apoptosis at a much 
lower extent than treatment with Herceptin or doxorubicin [33]. 
Thus, to test whether EDIA could fulfil the therapeutic need of cancer 
patients ineligible to Herceptin treatment due to cardiac dysfunction and 
primary or acquired Herceptin-resistance, we implemented new pre-clinical 
protocols to assess their cardiotoxic effects in combination with anthracyclines 
on human fetal cardiomyocytes in vitro, and in animal models in vivo.  
Moreover, we investigated the potential therapeutic use of EDIA by 
comparing their cardiotoxic effects with those of all the other available anti-
ErbB2 drugs, such as Herceptin, 2C4 (Pertuzumab) and Lapatinib. Finally, to 
investigate the molecular basis of the different cardiotoxic effects among the 
different ErbB2 inhibitors, we analyzed in the present study the effects of Erb-
hcAb on the formation of the HRG/ErbB2/ErbB4 complex and on the activation 
of its downstream signaling in comparison with those of Herceptin, 2C4 
(Pertuzumab) and Lapatinib. We report herein that the ErbB2-ErbB4 signaling 
pathway, activated by HRG in cardiac cells, is not affected by Erb-hcAb. These 
data may have important implications for the mechanism and treatment of anti-
ErbB2-induced cardiotoxicity. 
Materials and Methods 
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2. MATERIALS AND METHODS  
 
2.1 Antibodies and cell lines 
The hybridoma cells producing 2C4 antibody (LGC Promochem, Sesto 
San Giovanni, Italy) were grown in DMEM-RPMI-1640 medium in a 1:1 ratio 
(Sigma, St Louis, MO, USA). 
The H9C2 cardiomyoblasts were cultured in DMEM containing sodium 
pyruvate (1.0 mM). The media were supplemented with 10% heat-inactivated 
fetal bovine serum, 2.0 mM L-Glutammine, 50 Units/ml penicillin, and 50 
μg/ml streptomycin (all from Sigma). 
The Human Fetal Cardiac Myocytes (HFC) (Innoprot, Derio, Spain), 
were cultured according to the manufacturer’s recommendations. 
The antibodies used were: Herceptin (Genentech, South San Francisco, 
CA, USA); Erb-hcAb, produced from PER.C6® cells (Crucell N.V., Leiden, 
Netherlands) transfected with the recombinant vector and purified as previously 
described [27]. Erb-hRNase was produced and purified, as previously reported 
[26].  
The antibody 2C4 was produced and purified as follows. 2C4 
hybridoma cells were expanded to near confluence in complete medium, and 
then grown for 3–4 days in serum-free medium. The secreted antibody was 
purified from culture medium by affinity chromatography on a protein G-
Sepharose loaded with 300–500 ml of conditioned medium. Wash and elution 
steps were carried out as described for Erb-hcAb [27]. 
 
2.2 ELISA Assays  
Cells, harvested in non-enzymatic dissociation solution (Sigma), were 
washed and tranferred to U-bottom microtiter plates (2 x 105 cells per well). 
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After blocking with PBS containing 6% bovine serum albumin (BSA), cells 
were treated with the antibodies in ELISA buffer (PBS/BSA 3%) for 90 
minutes. After centrifugation and removal of supernatants, the pelleted cells 
were washed twice in 200 μl of ELISA buffer, resuspended in 100 μl of ELISA 
buffer, and incubated with peroxidase-conjugated anti-human IgG (Fc-specific) 
or anti-mouse antibody (Sigma) for detection of Herceptin and Erb-hcAb or 
2C4, respectively. After 1 h, the plates were centrifuged, washed with ELISA 
buffer, and reacted with 3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma). 
Binding values were determined from the absorbance at 450 nm, and reported 
as the mean of at least three determinations (standard deviation < 5%). Standard 
deviations were calculated on the basis of the results obtained by three different 
experiments. 
 
2.3 Intracellular levels of p-Akt/Akt and p-Erk/Erk 
H9C2 or HFC cells were seeded in 6-well plates at a density of 6x105 
cells/wells, incubated at 37°C and allowed to attach overnight. The following 
day cells were starved for 2 h in growth medium without serum, then briefly 
washed with PBS, and finally treated with 100 nM of each antibody diluted in 
RPMI medium, containing 10 mM Hepes (pH 7.2), 0,2% w/v BSA (binding 
buffer). After 1h at room temperature, the cells were incubated in the absence or 
in the presence of HRG (5 nM) for 10min at 25 C°. Supernatant was removed 
by aspiration and the cells were lysed in RPMI medium, containing 10mM 
HEPES (pH 7.2), 1,0% Triton x-100, 1% CHAPS, 2% sodium ortovanadate and 
protease inhibitor (Roche). Protein concentration was determined by the 
Bradford colorimetric assay (Sigma). Aliquots of 100 μg were run on 12 % 
SDS-PAGE, electroblotted onto PVDF membranes (Millipore Corporation, 
Bedford, MA, USA), which were treated with anti-pErk, anti-Erk, anti-pAkt or 
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anti-Akt antibodies (all from SantaCruz Biotecn. CA. USA), followed by anti-
mouse or anti-rabbit, HRP-conjugated IgGs, respectively. The signal from 
secondary antibodies was visualized by enhanced chemiluminescence detection 
(ECL western blotting detection kit, Amersham Biosciences). The signal 
intensity of reactive bands was quantitatively measured with a phosphorimager 
(GS-710, Biorad, Hercules, CA, USA). 
 
2.4 Immunoprecipitation and Western blotting Analyses 
ErbB2/ErbB4 co-immunoprecipitation was carried out by incubating 
cell lysates (prepared as described above) with 10 µg/ml of Herceptin, 2C4 or 
ERB-hcAb in PBS for 16 h at 4°C. The immune complexes were then collected 
by adsorption to protein A-Sepharose (Sigma) for 1 h at 4°C. After four washes 
with PBS, the proteins were released by boiling in loading buffer, run on 8% 
SDS-PAGE, and electroblotted onto PVDF membranes (Millipore Corporation, 
Bedford, MA, USA). The ErbB4 protein was detected by using the anti-ErbB4 
mAb (Santa Cruz Biotecn.). 
 
2.5 In Vitro cardiotoxicity tests 
To test the cardiotoxicity of Erb-hcAb, Herceptin, Lapatinib (Tykerb®, 
GlaxoSmithKline, Brentford, UK) and 2C4, HFC or H9C2 cells were seeded in 
96-well microtiter plates at a density of 1x104 cells/wells, and allowed to adhere 
overnight. Following the initial incubation for 16 h at 37°C, the medium was 
replaced with medium containing Herceptin, Erb-hcAb, 2C4 or Lapatinib in the 
absence or in the presence of HRG (5nM). After the treatment carried out for 72 
h at 37 °C, cells were washed with PBS and stained with Trypan Blue or tested 
by (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) 
for the determination of cell survival, as previously described [33]. 
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Cell survival was expressed as percent of viable cells in the presence of 
drugs under test with respect to control cultures grown in the absence of the 
drugs. Typically, cell survival values were obtained from at least three 
independent experiments in which five determinations were performed for each 
sample. Standard Deviations were calculated on the basis of the results obtained 
from all the experiments. 
 
2.6 Cell morphology analysis 
HFC cells were plated at a density of 6 ×105/well in six-well plates and 
incubated at 37°C with Herceptin (2 µM), Erb-hcAb (2 µM), doxorubicin (0.5 
µM), or with the combination of each antibody with doxorubicin. After 24 h, 
cultured cells were observed by light microscopy (Nikon ECLIPSE E1000, 
Melville, NY, USA), and photographed (Nikon digital camera DXM 1200F), to 
analyze cell morphology.  
 
2.7 Transthoracic echocardiography 
In vivo cardiac function was assessed by transthoracic echocardiography 
in sedated 7 wk old WT C57Bl/6 mice (Harlan Italy, San Piero al Natisone, 
UD, Italy) using a Vevo 2100 high-resolution imaging system (VisualSonics, 
Toronto, ON, Canada). Mice were anesthetized with Tilotamine (0.09 mg/g), 
Zolazepam (0.09 mg/g), and 0.01% atropine (0.04 ml/g). Cardiac function was 
evaluated by noninvasive echocardiography in basal condition and after 
intraperitoneal treatment of equimolar doses (2 nmol/mouse) of Herceptin, Erb-
hcAb, immunoRNase, 2C4; or doxorubicin (15 mg/kg), used as a positive 
control. Oral treatment was carried out for the Tyrosine Kinase Inhibitor 
Lapatinib (100 mg/kg/day). The left ventricular (LV) echocardiogram was 
assessed in both parasternal long-axis and short-axis views at a frame rate of 
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233 Hz. End-systole and end-diastole dimensions were defined as the phases 
corresponding to the ECG T wave, and to the R wave, respectively. M-mode 
LV end-systolic dimensions (LVESDs) and LV end-diastolic dimensions 
(LVEDDs) were averaged from 3–5 beats. Left ventricular end-diastolic 
dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) 
were measured from the LV M-mode at the midpapillary muscle level. 
Fractional shortening percentage (%FS) was calculated as [(LVEDD-
LVESD)/LVEDD] x100 [34]. Radial strain (SR) was evaluated by speckle 
tracking echocardiography, a novel technique that enables the assessment of 
myocardial strain (an index of myocardial deformation) through the analysis of 
speckle motion inherently present in a standard, 2-D echocardiographic image 
[35].  
Studies and analyses were performed blinded to heart condition. Data 
are presented as mean±SD unless otherwise noted. Between group differences 
were assessed by Student’s t-test or one-way ANOVA as appropriate. Statistical 
significance was defined as p<0.05. 
The animal experimentations described herein were conducted in 
accordance with the Italian regulation for experimentation on animals. All in 
vivo experiments were carried out with ethical committee approval and met the 
standards required by the Directive 2010/63/EU of the European Parliament. 
 
2.8 Cardiac Fibrosis Analysis  
Interstitial fibrosis was evaluated by staining of 5 μm-tick tissue 
sections with 1% Sirius red in picric acid (Carlo Erba Laboratories, Milan, 
Italy) as previously described [36]. The positively stained (red) fibrotic area 
was measured using a computer-assisted image analysis system (Nikon NIS 
ELEMENTS BRV, Melville, NY, USA) and expressed as a percentage of total 
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area. The percentage of red staining was calculated from 3 samples/group, with 
2 sections for each sample and 5 images for each section.
Results 
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3. RESULTS 
 
3.1 Binding of anti-ErbB2 antibodies to rat and human cardiac cells 
As previously reported [33], Erb-hcAb and Herceptin were both capable 
of binding to ErbB2 receptor on rat and mouse cardiomyocytes. Here we tested 
if they were also capable of recognizing ErbB2 receptor on Human Fetal 
Cardiomyocytes (HFC). Furthermore, for a comparison with Pertuzumab, the 
other humanized anti-ErbB2 antibody currently tested in clinical trials, we used 
also its cognate mouse antibody 2C4, and tested if it was capable of binding 
ErbB2 both on rat H9C2 cardiomyoblasts and HFC. These experiments were 
carried out by immunoprecipitation assays performed by incubating the anti-
ErbB2 antibodies with protein cell extracts of HFC, and for 2C4, also with 
extracts of H9C2 cardiomyoblasts. The immune complexes were collected by 
protein A-Sepharose and analyzed by Western blotting with Neu, a commercial 
anti-ErbB2 mAb. 
As shown in figure 4 A, Erb-hcAb and Herceptin were capable of 
immunoprecipitating ErbB2 from HFC, and 2C4 recognized ErbB2 from both 
human fetal cardiomyocytes and H9C2 cardiomyoblasts (Figure 4 A,B).  
These results were confirmed by ELISA assays, performed by testing 
Erb-hcAb, Herceptin and 2C4 for their binding to HFC at increasing 
concentrations. 
The binding curves obtained for Erb-hcAb, Herceptin or 2C4 on HFC 
were found to be superimposable (figure 4 C), thus suggesting that the 
antibodies recognize human ErbB2 with comparable affinity. 
The antibody 2C4 was tested by ELISA assays also on H9C2 
cardiomyoblasts and showed the ability to bind the receptor also on these cells 
(figure 4 D). 
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3.2 In vitro effects of the anti-ErbB2 immunoagents on human cardiac cells 
To test the cardiotoxicity of Erb-hcAb and Erb-hRNase on HFC, the 
cells were incubated at 37°C in the absence or in the presence of increasing 
concentrations of immunoagents for 24 hours and then either tested by MTT 
assays or counted to measure cell viability. Control tests, carried out in parallel 
assays with Herceptin, 2C4 (the mouse antibody version of Pertuzumab), 
Lapatinib or doxorubicin are presented for comparison. 
As shown in Fig. 5, Erb-hcAb and Erb-hRNase did not show cardiotoxic 
effects, whereas Herceptin, 2C4, Lapatinib and doxorubicin were all found to 
be significantly toxic for cardiac cells.  
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Figure 4: Binding of the antibodies to human and rat ErbB2. Western 
blotting analyses with Neu, an anti-ErbB2 mAb of cell extracts from 
HFC (A), previously immunoprecipitated with Erb-hcAb, Herceptin or 
2C4, and from H9C2 (B) immunoprecipitated with  2C4. Binding 
curves of Herceptin (squares), Erb-hcAb (circles) or 2C4 (triangles) to 
HFC (C) and H9C2 cardiomyoblasts (D). 
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Figure 5: Effects of the anti-ErbB2 drugs on human fetal 
cardiomyocytes (HFC). Dose-response tests of the cells treated 
for 24h with Herceptin, Erb-hcAb, ImmunoRNase, 2C4, 
Lapatinib or Doxorubicin used as a positive control. 
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3.3 Effects of the anti-ErbB2 drugs on ligand-induced growth of cardiac 
cells 
When we treated H9C2 cardiomyoblasts or HFC with the ErbB4 ligand 
HRG, a significant growth stimulation (between 120% and 150% of control 
growth) was observed. We then tested the inhibitory effects of all the 
investigated anti-ErbB2 drugs by adding the antibodies or Lapatinib at the 
concentrations reported in Figure 6, in the absence or in the presence of HRG. 
As shown in Figure 6, the antibodies 2C4 and Herceptin, and the kinase 
inhibitor Lapatinib inhibited the growth of HFC and H9C2 in a dose dependent 
manner either in the absence or in the presence of HRG. On the contrary, Erb-
hcAb did not show toxic effects in the absence of HRG and did not inhibit the 
ligand induced growth stimulation. 
 
3.4 Effects of the anti-ErbB2 antibodies on the association of ErbB2 with 
ErbB4 in cardiac cells 
We studied whether ErbB4-ErbB2 complexes exist on the plasma 
membrane in the absence of the ErbB4 ligand, HRG. To answer this question, 
HFC and H9C2 cells were treated with HRG or control buffer, and lysed. 
Immunoprecipitation was performed by adding an anti-ErbB2 antibody that 
recognizes the intracellular domain of ErbB2. The immunoprecipitated proteins 
were then analyzed by Western blotting with an anti-ErbB4 monoclonal 
antibody. As shown in figure 7, ErbB4 was detected in ErbB2 
immunoprecipitates only when the cardiac cell cultures were treated with the 
ErbB4 ligand HRG. These data suggest that the recruitment of ErbB2 to ErbB4 
occurs in a HRG-dependent manner. 
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We then studied whether antibodies to the extracellular domain of 
ErbB2 were capable of disrupting the formation of ErbB4-HRG-ErbB2 
complexes. The antibodies to ErbB2 used in these studies, Herceptin, Erb-hcAb 
and 2C4, are known to bind distinct epitopes on the extracellular domain of the 
ErbB2 receptor [31, 32, 37]. 
As shown in figure 7, Herceptin and 2C4 were capable of disrupting the 
formation of ligand-mediated ErbB4-ErbB2 complex, whereas Erb-hcAb did 
not show any effects on the ErbB2-ErbB4 heterodimerization. 
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Figure 6: Effects of the anti-ErbB2 drugs on the proliferation of HFC (A-
D) and H9C2 (E-H) in the absence (white bars) or in the presence (black 
bars) of HRG. 
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Figure 7: Association of ErbB2 with ErbB4 in the absence or in the 
presence of HRG in cardiac cells treated with the indicated 
antibodies. 
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3.5 Effects of the anti-ErbB2 drugs on ligand-activated ErbB2 signaling in 
cardiac cell lines 
Since ErbB4 requires the association with ErbB2 to initiate signal 
transduction in cardiac cells, we determined the effects of anti-ErbB2 antibodies 
and Lapatinib on receptor activation. With this aim we assessed the effects of 
anti-ErbB2 antibodies on MAPK activation, a downstream target of ErbB2. 
Briefly, HFC and H9C2 cells were treated with HRG in the absence or in the 
presence of the antibodies or Lapatinib, and then lysed. MAPK activation was 
measured by western blotting of lysates with a phospho-specific MAPK 
antibody. As shown in Figure 8, cells treated with HRG showed a strong 
activation of MAPK (Erk1, Erk2) which was strongly reduced by 2C4 , 
Herceptin and Lapatinib treatment, whereas it was unaffected by Erb-hcAb.  
To test the effects of anti-ErbB2 monoclonal antibodies or Lapatinib on 
PI3 kinase activation, another pathway downstream ErbB2 in cardiac cells [23], 
HFC and H9C2 cells were treated as described above, and the activity of the 
downstream Akt kinase was measured by Western blotting with a phospho-
specific Akt antibody. As shown in Figure 8, the treatment of cardiac cells with 
the ErbB4 ligand, HRG, results in the activation of Akt that is inhibited by the 
pretreatment with 2C4, Herceptin or Lapatinib, but it is not affected by Erb-
hcAb. 
These results suggest that Herceptin, 2C4 and Lapatinib exert their 
cardiotoxic effects by inhibiting the pathways downstream ErbB2-ErbB4 
complexes upon activation by HRG, whereas Erb-hcAb does not show 
cardiotoxic effects because it does not inhibit the ErbB2-ErbB4 
heterodimerization and its downstream signaling activation induced by HRG. 
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Figure 8: Effects on  MAPK and Akt activation in HFC (A-D) and H9C2 
(E-H), as exerted by the indicated drugs in the absence or in the presence of 
the ligand HRG. 
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3.6 Effects on cell survival of Erbicin-derived immunoagents in 
combination with doxorubicin 
Large-scale clinical studies with Herceptin have shown that up to 7 % of 
patients suffer from cardiac dysfunction when Herceptin is used in 
monotherapy, and this percentage raises to 28% when it is combined with 
anthracyclines [9-11]. 
Thus, we performed experiments to evaluate the effects of the 
combination of Erb-hcAb or Erb-hRNase with doxorubicin on HFC and on a rat 
H9C2 cardiomyoblast cell line.  
Cytotoxicity assays were carried out on cells treated for 24 h at 37°C 
with either doxorubicin (0.12-0.5 μM), or Erb-hcAb (0.25-2 μM) or with a 
combination of the chemotherapeutic drug and Erb-hcAb at the same 
concentrations. Results of control tests run with Herceptin and doxorubicin are 
presented for comparison. We found that the toxicity was clearly superior when 
the chemotherapeutic drug was given in combination with Herceptin (see Fig. 
9), whereas no additive effects were observed for the combination of Erb-hcAb 
with doxorubicin. 
Figure 10 shows the morphologic changes of cells treated for 24 h at 
37°C with Herceptin (2 μM), Erb-hcAb (2 μM), doxorubicin (0.5μM), or with 
the combination of each immunoagent with doxorubicin at the same 
concentrations. The combinatorial treatment of Herceptin and doxorubicin 
clearly caused an increased cell death and more marked changes in cell 
morphology than each drug alone, as cells appeared to lose their typical features 
and assume distorted, round shaped forms. No such effects were observed for 
the cells treated with Erb-hcAb alone or in combination with doxorubicin.  
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Similar experiments were performed with the immunoRNase Erb-
hRNase. Human fetal cardiomyocytes and rat H9C2 cardiomyoblasts were 
treated for 24 h at 37°C with either doxorubicin (0.12-0.5 μM), or Erb-hRNase 
(0.25-2 μM) or with a combination of doxorubicin with Erb-hRNase at the same 
concentrations. As shown in Fig. 11, doxorubicin displayed a similar cytotoxic 
effect when used alone or in combination with Erb-hRNase, thus suggesting that 
also this immunoagent, differently from Herceptin, does not increase the 
cardiotoxicity of the chemotherapeutic treatment. 
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Figure 9: Effects of combination treatment of Herceptin (A, B, E, F) 
or Erb-hcAb (C, D, G, H) with doxorubicin on human fetal 
cardiomyocytes (HFC) and H9C2 cardiomyoblasts. Dose-response 
tests of the indicated cells treated for 24h with each antibody alone 
(black bars), doxorubicin alone (grey bars) or with the combination 
of each antibody and doxorubicin (striped bars). 
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Figure 10: Effects on cell morphology of human fetal cardiomyocytes 
(HFC) grown for 3 days in the absence (control) or in the presence of 
Herceptin, Erb-hcAb, doxorubicin  or with the combinations of each 
antibody with doxorubicin. Bar, 10 μm. 
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Figure 11: Effects of combination treatment of Erb-hRNase with 
doxorubicin on human fetal cardiomyocytes (HFC) and H9C2 
cardiomyoblasts. Dose-response tests of the indicated cells treated for 
24h with Erb-hRNase alone (black bars), doxorubicin alone  (grey bars) 
or with the combination of Erb-hRNase and doxorubicin (striped bars). 
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3.7 In vivo cardiotoxic effects 
We then tested the effects of combination of Herceptin, Erb-hcAb, or 
Erb-hRNase with doxorubicin, on a mouse model. For these experiments, 
groups of 6-10 mice were injected with equimolar doses of Erbicin-derived 
immunoagents or Herceptin, used either as single agents or in combination with 
doxorubicin. Echocardiography measurements were performed on mouse hearts 
before and after treatment. Erb-hcAb and the immunoRNase, each used in 
monotherapy, had no effects on cardiac function: FS (Fig. 12, panel A) and 
radial strain RS (Figure 12, panel B) were not affected; only a slight reduction 
of radial strain in the group treated for 7 days with Erb-hcAb is shown but the 
difference was found to be not statistically relevant. When combined with 
doxorubicin, EDIA showed no additive effects with respect to those of 
doxorubicin alone. Indeed, FS was reduced to 52±0.2% early (after 2 days) also 
in mice treated with doxorubicin in monotherapy (2.17 mg/kg/day). On the 
other hand, mice treated with a combination of doxorubicin (2.17mg/kg/day) 
and Herceptin (2.25 mg/kg/day) showed a drastic reduction of FS (49±2%, vs 
60±0.4% in sham), and in mice treated with Herceptin alone (2.25 mg/kg/day) 
FS decreased at 7 days (49±1.5% vs 60±0.5%, p=0.002). In contrast, after 2 
days, myocardial strain was already reduced not only in groups of mice treated 
with doxorubicin or doxorubicin combined with Herceptin, but also in groups 
treated with Herceptin alone (43± 1% vs 66±0.6% in sham). 
To further confirm that radial strain is an early predictor of future onset 
of cardiac dysfunction, we tested the in vivo effects on this parameter of 
Lapatinib and 2C4 (the mouse antibody version of Pertuzumab), previously 
reported [15, 16] as less cardiotoxic ErbB2-inhibitors. As shown in Fig. 13 
panel A, both FS and radial strain were reduced by treatment with 2C4. After 2 
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days of treatment with 2C4 (2.25 mg/kg/day), myocardial strain was already 
decreased compared to sham: 40±8% vs 66±0.6%, (p=0.02), with FS also 
significantly reduced: 58±1% vs 60±0.4, (p=0.01). LV dysfunction was 
exacerbated after 7 days of treatment, with strain further decreasing to 31±7%, 
and FS to 39±5% (Fig. 13, panel A).  
In mice treated with Lapatinib (100mg/kg/day) a decrease of FS was 
observed after 7 days (56±2% vs 60±1% for sham animals, p=0.04), while after 
2 days FS was unaffected. At this time point radial strain, evaluated by speckle 
tracking, was able to identify cardiotoxicity at a very early stage (34±7% vs 
59±1% in sham, p=0.008) (Fig. 13, panel B).  
After treatment, mice were sacrificed, and the hearts were removed and 
subjected to weight measurement, histological examination, and processing for 
detection of myocardial stress. Cardiac fibrosis, induced by 2C4 and Lapatinib, 
was examined by the Sirius red staining for collagen on 5-µm-thick tissue 
sections, as previously described for the treatment with Erb-hcAb or Herceptin 
[33]. The red-stained sections were assessed for the presence of fibrosis 
(collagen) in the heart tissues using computer-assisted image analysis to 
evaluate the percentage of the red staining. All analyses were carried out in 
parallel experiments on control untreated mice. As shown in Fig. 14, cardiac 
fibrosis was significantly increased in mouse hearts treated either with 
Lapatinib or 2C4 for 7 days with respect to control untreated mice. 
As previously reported [33], also Trastuzumab and doxorubicin were 
found to induce cardiac fibrosis at higher extent than that shown in mice 
untreated or treated with EDIA. 
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Figure 12: In vivo effects of combinations of anti-ErbB2 
immunoagents with doxorubicin on heart function. Relative FS 
and radial strain are reported before or after the treatment of mice 
for 2 or 7 days with immunoRNase, Herceptin, or Erb-hcAb used 
as single agents or in combination with doxorubicin. *P≤ 0.05. 
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Figure 13: In vivo effects of 2C4 (Pertuzumab) and Lapatinib on 
heart function. Relative FS and radial strain are reported before or 
after the treatment of mice for 2 or 7 days with the anti-ErbB2 2C4 
mAb antibody (panel A, *P≤ 0.02) or with Lapatinib, the Tyrosine 
Kinase inhibitor (panel B, *P ≤ 0.04). 
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Figure 14: Analysis of cardiac fibrosis in mice treated with Lapatinib 
(Lap) or 2C4. Panel A: representative photomicrographs of LV sections 
from mice treated with the indicated drugs. Panel B: quantification of the 
interstitial fibrosis expressed as relative percentage of color intensity. 
(*p=0.02; **p=0.008 vs sham). 
 
Discussion/Conclusions 
34 
4. DISCUSSION/CONCLUSIONS 
 
In the last decades, novel anticancer drugs have been successfully 
developed that effectively induce tumor regression or growth delay, thus 
prolonging patients survival time. 
However, cardiovascular obnoxious side effects of the new anticancer 
drugs have been shown that can lead to therapy-related heart failure. Although 
cardiac problems were predictable for anthracyclines, they were instead totally 
unexpected from highly targeted anticancer agents, such as Herceptin or 
tyrosine kinase inhibitors. 
Since its registration by the Food and Drug Administration (FDA) in 
1998, Herceptin (Herceptin, Genentech, San Francisco, CA) has been used to 
treat more than 450,000 women with breast cancer worldwide [38]. As a 
monoclonal antibody directed against the human epidermal growth factor 
receptor-2 (HER-2 or ErbB2), Herceptin was initially shown to prolong the 
survival of women with HER-2 positive advanced breast cancer [10]. In 2005, 
landmark adjuvant studies demonstrated that adjuvant Herceptin either 
following or in combination with chemotherapy reduced the risk of relapse by 
approximately 50% and the risk of death by 33% for women with HER-2 
positive early breast cancer [39]. 
Cardiac toxicity was recognized as an important side effect at an early 
stage in the development of Herceptin. Manifested as symptomatic congestive 
heart failure (CHF) or asymptomatic left ventricular ejection fraction (LVEF) 
decline, Herceptin-induced cardiotoxicity has been attributed to blockade of 
HER-2 signaling in cardiac myocytes. The cardiac safety of anti-HER-2 therapy 
is likely to be agent specific, as the early clinical experience with Lapatinib, a 
dual tyrosine kinase inhibitor of the EGFR and HER-2 receptors, suggests that 
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it may produce less cardiotoxicity compared with Herceptin. However, more 
studies are needed to better characterize the cardiac effects of Lapatinib, since 
the patient population studied was heterogeneous and highly selected, limiting 
the conclusions that can be drawn from this early data [40].  
A new anti-ErbB2 monoclonal antibody which recognizes an epitope 
distant from that of Herceptin (in the extracellular portion of ErbB2), 
Pertuzumab, does not seem to be significantly cardiotoxic [15], but data are still 
very preliminary, since it is still being tested in pivotal clinical trials. 
This awareness has led on one hand to search for novel and safe 
antitumor drugs devoid of cardiac side effects, and on the other to the 
development of novel non-invasive but more sensitive methods for the early 
screening of cardiac dysfunction. 
Here we report on a comparative analysis of the cardiotoxic effects of 
EDIA, the novel human immunoagents targeting a novel epitope of ErbB2 [31, 
32], different from those of other anti-ErbB2 antibodies or inhibitors currently 
in clinical use or trials for breast cancer therapy. 
We show here for the first time that EDIA do not show in vitro toxic 
effects on human fetal cardiomyocytes in stark contrast to the prototypical 
antibody Herceptin. Surprisingly, also 2C4 (Pertuzumab) and Lapatinib, an 
anti-ErbB2 drug which inhibits directly its intracellular tyrosine kinase domain, 
were found to be toxic in a dose dependent fashion on HFC. Similar results 
were obtained for EDIA when they were tested in combination with 
doxorubicin, as they did not show additive toxic effects. Different results were 
obtained with Herceptin, which instead increased the toxicity of doxorubicin, 
according to previous studies [10]. 
It was also previously reported in literature [18] that Herceptin is toxic 
to cultured human atrial cardiac microfragments maintained by co-culture with 
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feeder cells from newborn rat heart, as it caused a complete loss of their healthy 
beating phenotype and tissue structure.  Antibody-mediated inhibition of ErbB2 
might regulate mitochondrial integrity through the BCL-X proteins, leading to 
ATP depletion and contractile dysfunction without profound changes in 
myocyte ultrastructure [14]. 
As for the different effects on cardiomyocytes of not toxic Erb-hcAb, 
and strongly toxic Herceptin, our previous data on rat cardiomyocytes indicate 
that it can be ascribed to their different apoptotic properties. Herceptin induces 
apoptosis in cardiac cells, as it lowers the level of Bcl-XL and activates caspase 
3, whereas Erb-hcAb does not induce apoptosis [33]. 
In the present work we provide direct evidence that the cardiotoxic 
effects of Herceptin and Pertuzumab are based on their ability to prevent the 
assembly of HRG/ErbB2/ErbB4 complex, required for cardiomyocyte survival. 
On the contrary, Erb-hcAb does not inhibit the ErbB2-ErbB4 
heterodimerization induced by HRG. This difference is probably due to the 
different epitopes of ErbB2 recognized by the three antibodies. 
Consequently, Herceptin and Pertuzumab, differently from Erb-hcAb, 
affect also the ErbB2-ErbB4 signaling pathway by inhibiting MAPK (Erk1, 
Erk2) and Akt in a similar fashion to Lapatinib.  
Mouse models were then used to monitor the in vivo cardiotoxicity of 
the anti-ErbB2 drugs and to validate speckle tracking echocardiography as a 
sensitive measure of myocardial function in animal models. EDIA did not 
impair cardiac function in vivo as they did not affect radial strain and fractional 
shortening. The latter parameter was evaluated here for the first time after the 
treatment of mice with EDIA to assess whether it could be used as a more 
sensitive method to predict cardiac dysfunction. 
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Indeed, in mice treated with Herceptin, 2C4 or Lapatinib alterations of 
RS preceded the reduction of conventional echocardiography markers, such as 
FS and LVEF. In particular, Herceptin in a fashion similar to doxorubicin 
reduced radial strain at two days and fractional shortening at seven days of 
treatment compared to the sham group. 
Similar results are shown here for 2C4 (Pertuzumab) and Lapatinib, 
previously reported in literature [15, 16] as anti-ErbB2 drugs less cardiotoxic 
than Herceptin, thus confirming that limited number of clinical studies 
performed with these newer agents only provide us with partial and very 
preliminary results. Indeed radial strain, as evaluated by speckle tracking, was 
capable of identifying early cardiotoxicity after only two days of treatment with 
either 2C4 or Lapatinib. 
As of today, traditional echocardiographic indexes of cardiac function 
such as FS and EF can identify patients in which Herceptin toxicity is already 
evident. Also, troponins proposed by other authors [41] can be already elevated 
following anthracyclines, therefore the secondary administration of Herceptin 
does not act as the cause of myocardial stress, but only as a modulator of 
anthracyclines’stress [42]. At the moment, besides the recognition of cardiac 
risk factors, there is not yet a bona fide none invasive tool that can discriminate 
patients who will develop cardiotoxicity by treatment with Herceptin. A very 
interesting study [43] has recently indicated that Doppler Tissue Imaging (DTI) 
can detect early LV dysfunction prior to alterations seen in conventional 
echocardiographic indices in an animal model of anthracycline and Herceptin–
mediated cardiomyopathy. Of course, further studies will be needed to validate 
DTI and radial strain as useful tools in these settings. 
In conclusion, the present in vitro and in vivo studies confirm that EDIA 
may fulfill the therapeutic need of patients ineligible to Herceptin treatment due 
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to cardiac dysfunction, and strongly indicate that Radial Strain, measured by 
Speckle Tracking echocardiography, could become a reliable marker for early 
detection of myocardial subtle changes, predicting cardiac dysfunction in 
advance.  
Furthermore, the data on the mechanisms of action of the different 
ErbB2 inhibitors may have important implications for the treatment of anti-
ErbB2-induced cardiotoxicity, as they provide for the first time the molecular 
basis of the cardiotoxic effects of Herceptin and the other available anti-ErbB2 
drugs. 
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